ONLINE SUPPLEMENTARY DATA

Supplementary Table 1. Correlation of Baseline And Change From Baseline to Week 12 Values Among Patients With Leeds, MASES, or SPARCC Score >0 at Baseline.

	Pearson Correlation Coefficient of Baseline Values			Pearson Correlation Coefficient of Change to Week 12 Values*		
	Leeds (LEI) (n=103)	MASES (n=123)	SPARCC (n=129)	Leeds (LEI) (n=102)	MASES (n=122)	SPARCC (n=128)
BASDAI question 4	0.269 *P*=.006	0.253 *P*=.005	0.292 *P*<.001	0.158 *P*=.116	0.248 *P*=.006	0.235 *P*=.008
BASDAI question 2	0.027 *P*=.788	0.159 *P*=.078	0.055 *P*=.534	0.148 *P*=.140	0.215 *P*=.018	0.178 *P*=.045
Patient global	0.271 *P*=.006	0.318 *P*<.001	0.238 *P*=.007	0.129 *P*=.200	0.216 *P*=.018	0.139 *P*=.122
Physician global	0.146 *P*=.141	0.155 *P*=.087	0.122 *P*=.168	0.172 *P*=.084	0.139 *P*=.126	0.280 *P*=.001
CRP	−0.143 *P*=.149	0.043 *P*=.633	−0.047 *P*=.597	−0.014 *P*=.889	0.073 *P*=.431	0.056 *P*=.535
SF-36 PCS	−0.174 *P*=.079	−0.211 *P*=.019	−0.159 *P*=.072	−0.086 *P*=.393	−0.157 *P*=.087	−0.171 *P*=.055
SF-36 MCS	−0.207 *P*=.036	−0.072 *P*=.426	−0.118 *P*=.182	−0.158 *P*=.116	−0.036 *P*=.698	−0.034 *P*=.705
TJC	0.616 *P*<.0001	0.605 *P*<.0001	0.710 *P*<.0001	0.267 *P*=.007	0.377 *P*<.0001	0.472 *P*<.0001
SJC	0.328 *P*<.001	0.313 *P*<.001	0.453 *P*<.0001	0.228 *P*=.021	0.209 *P*=.021	0.415 *P*<.0001
HAQ-S	0.210 *P*=.034	0.311 *P*<.001	0.265 *P*=.002	0.111 *P*=.267	0.134 *P*=.142	0.201 *P*=.023

BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; HAQ-S, Health Assessment Questionnaire for spondyloarthropathy; LEI, Leeds Enthesitis Index; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; MCS, Mental Component Summary; PCS, Physical Component Summary; SF-36, 36-item Short-Form; SJC, swollen joint count; SPARCC, Spondyloarthritis Research Consortium of Canada;TJC, tender joint count. *1 patient missing data in each group for BASDAI question 4, BASDAI question 2, and HAQ-S; 2 patients missing data in each group for patient global, SF-36 PCS, SF-36 PCS; for CRP, data were missing from 1 patient in the Leeds group, 2 patients in the MASES group, and 1 patient in the SPARCC group.

Supplementary Figure 1. Longitudinal Analysis for LEI, SPARCC and MASES. Mixed-effects longitudinal model with both fixed effects and a hybrid covariance structure for random effects for patients who had LEI, MASES or SPARCC enthesitis score >0 at baseline. Fixed effects included treatment group (factor), week of visits (factor), and their interactions. The hybrid covariance structure included random intercepts accounting for different baseline values for distinct patients as well as exponential spatial covariance accounting for (correlated) repeated measures within a patient. EOW, every other week; LEI, Leeds enthesitis index; LS, least square; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; SE, standard error; SPARCC, SPondyloArthritis Research Consortium of Canada Enthesitis Index. Arrows indicate end of double-blind period and beginning of open-label adalimumab treatment in all patients (including those treated with placebo at weeks 0 –12).